Defining therapeutic targets for liver fibrosis: Exploiting the biology of inflammation and repair

Pharmacological Research

Volumn 58, Issue 2, 2008, Pages 129-136

  Iredale, John ^a  

^a MRC CIR ^*  (United Kingdom)

Author keywords

Antifibrotic; Apoptosis; Fibrosis resolution; Hepatic stellate cell; Inflammation; Liver fibrosis; Liver injury; Macrophages; Matrix degradation; Matrix synthesis; Mesenchymal stem cell; MMPs; Myofibroblast; Therapy; TIMPs

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

APOPTOSIS; CELL ISOLATION; CELL POPULATION; CYTOKINE PRODUCTION; GEOGRAPHIC DISTRIBUTION; HUMAN; INBORN ERROR OF METABOLISM; INFLAMMATION; INFLAMMATORY CELL; KNOCKOUT GENE; LIVER FIBROSIS; LIVER INJURY; MESENCHYMAL STEM CELL; MYOFIBROBLAST; NONALCOHOLIC FATTY LIVER; NONHUMAN; PARASITOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STELLATE CELL; TISSUE CULTURE; TRANSGENIC MOUSE; UNITED KINGDOM; VIRUS HEPATITIS; WOUND HEALING;

ANIMALS; CELL LINEAGE; CELL MOVEMENT; FIBROBLASTS; HEPATIC STELLATE CELLS; HUMANS; INFLAMMATION; LIVER CIRRHOSIS; LIVER REGENERATION; MATRIX METALLOPROTEINASES;

EID: 53449094645     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.06.011     Document Type: Review

References (82)

1. Friedman S.L., Roll F.J., Boyles J., and Bissell D.M. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 82 (1985) 8681-8685
2. Otto D.A., and Veech R.L. Isolation of a lipocyte-rich fraction from rat liver nonparenchymal cells. Adv Exp Med Biol 132 (1980) 509-517
3. Maher J.J., Bissell D.M., Friedman S.L., and Roll F.J. Collagen measured in primary cultures of normal rat hepatocytes derives from lipocytes within the monolayer. J Clin Invest 82 (1988) 450-459
4. Maher J.J., and McGuire R.F. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest 86 (1990) 1641-1648
5. Constandinou C., Henderson N., and Iredale J.P. Modelling liver fibrosis in rodents. Methods Mol Med 117 (2005) 237-250
6. Tsukamoto H., Matsuoka M., and French S.W. Experimental models of hepatic fibrosis: a review. Semin Liver Dis 10 (1990) 56-65
7. Anstee Q.M., and Goldin R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87 (2006) 1-16
8. Koteish A., and Diehl A.M. Animal models of steatosis. Semin Liver Dis 21 (2001) 89-104
9. Kirsch R., Clarkson V., Shephard E.G., et al. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 18 (2003) 1272-1282
10. Kulinski A., Vance D.E., and Vance J.E. A choline-deficient diet in mice inhibits neither the CDP-choine pathway for phosphatidylcholine synthesis in hepatocytes nor apolipoprotein B secretion. J Biol Chem 279 (2004) 23916-23924
11. Oliviera C.P., Gayotto L.C., Tatai C., et al. Vitamin C and vitamin E in prevention of nonalcoholic fatty liver disease (NAFLD) in choline deficient diet fed rats. Nutr J 2 (2003) 9-14
12. Raubenheimer P.J., Nyirenda M.J., and Walker B.R. A choline deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high fat diet. Diabetes 55 (2006) 2015-2020
13. Vig P., Russo F.P., Edwards R.J., et al. The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice. Hepatology 43 (2006) 316-324
14. Chisari F.V., Pinkert C.A., Miltch D.R., et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 230 (1985) 1157-1160
15. Friedman S.L., Rockey D.C., and Bissell D.M. Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology 45 1 (2007) 242-249
16. Iredale J.P. Models of Liver Fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. JCI 117 3 (2007) 539-549
17. Henderson N.C., and Iredale J.P. Liver fibrosis: cellular mechanisms of progression and resolution. J Clin Sci 112 (2007) 265-280
18. Gressner A.M., Weiskirchen R., Breitkopf K., and Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 7 (2002) d793-d807
19. Gao R., and Brigstock D.R. Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan. J Biol Chem 279 (2004) 8848-8855
20. Williams E.J., Gaca M.D., Brigstock D.R., Arthur M.J., and Benyon R.C. Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol 32 (2000) 754-761
21. Pinzani M., Gesualdo L., Sabbah G.M., and Abboud H.E. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest 84 (1989) 1786-1793
22. Friedman S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88 1 (2008) 125-172 [Review]
23. Forbes S.J., Russo F.P., Rey V., et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 126 (2004) 955-963
24. Russo F.P., Alison M.R., Bigger B.W., et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 130 (2006) 1807-1821
25. Kisseleva T., Uchinami H., Feirt N., et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 45 (2006) 429-438
26. Kinnman N., and Housset C. Peribiliary myofibroblasts in biliary type liver fibrosis. Front Biosci 7 (2002) 496-503
27. Knittel T., Cobold D., Saile B., et al. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 117 (1999) 1205-1221
28. Ramadori G., and Saile B. Mesenchymal cells in the liver-one cell type or two?. Liver 22 (2002) 283-294
29. Cassiman D., Libbrecht L., Desmet V., Denef C., and Roskams T. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 36 (2002) 200-209
30. Kalluri R., and Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112 (2003) 1776-1784 10.1172/JCI200320530
31. Wells R.G., Kruglov E., and Dranoff J.A. Autocrine release of TGF-beta by portal fiboblasts regulates cell growth. FEBS Lett 559 (2004) 107-110
32. Friedman S.L., Rockey D.C., McGuire R.F., et al. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology 15 (1992) 234-243
33. Iredale J.P., Benyon R.C., Arthur M.J., et al. TIMP-1 and interstitial collagenase expression in liver fibrosis; implications for pathogenesis. Hepatology 24 (1996) 176-184
34. Benyon R.C., and Arthur M.J. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 21 (2001) 373-384
35. Vyas S.K., Leyland H., Gentry J., and Arthur M.J. Rat hepatic lipocytes synthesize and secrete transin (stromelysin) in early primary culture. Gastroenterology 109 (1995) 889-898
36. Arthur M.J., Friedman S.L., Roll F.J., and Bissell D.M. Lipocytes from normal rat liver release aneutral metalloproteinase that degrades basement membrane (type IV) collagen. J Clin Invest 84 (1989) 1076-1085
37. Arthur M.J., Stanley A., Iredale J.P., et al. Secretion of 72 kDa type IV collagenase/gelatinase by cultured human lipocytes. Analysis of gene expression, protein synthesis and proteinase activity. Biochem J 287 (1992) 701-707
38. Benyon R.C., Iredale J.P., Goddard S., Winwood P.J., and Arthur M.J. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 110 (1996) 821-831
39. Benyon R.C., Hovell C., Da Gaca M., et al. Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology 30 (1999) 977-986
40. Iredale J.P., Murphy G., Hembry R.M., Friedman S.L., and Arthur M.J. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J Clin Invest 90 1 (1992) 282-287
41. Gaca M.D., Zhou X., Issa R., et al. Basement membrane-like matrix inhibits proliferation and collagen synthesis by activated rat hepatic stellate cells: evidence for matrix-dependent deactivation of stellate cells. Matrix Biol 22 (2003) 229-239
42. Zhou X., Murphy F.R., Gehdu N., et al. Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem 279 (2004) 23996-24006
43. Olaso S., Ikeda K., Eng F.J., et al. DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J Clin Invest 108 (2001) 1369-1378
44. Friedman S.L., Roll F.J., Boyles J., Arenson D.M., and Bissell D.M. Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix. J Biol Chem 264 (1989) 10756-10762
45. Zhou X., Jamil A., Nash A., et al. Impaired proteolysis of collagen I inhibits proliferation of hepatic stellate cells: Implication for regulation of liver fibrosis. J Biol Chem 281 (2006) 39757-39765
46. Wells R.G. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol 39 Suppl. 2 (2005) S158-S161
47. Rockey D.C. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 21 (2001) 337-349
48. Marra F. Hepatic stellate cells and the regulation of liver inflammation. J Hepatol 31 (1999) 1120-1130
49. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275 (2000) 2247-2250
50. Bataller R., Gines P., Nicolas J.M., et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118 (2000) 1149-1156
51. Rockey D.C. Cellular pathophysiology of portal hypertension and prospects for management with gene therapy. Clin Liver Dis 5 (2001) 851-865
52. Duffield J.S., Forbes S.J., Constandinou C., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115 (2005) 56-65
53. Canbay A., Tamir P., Torok N., et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 83 (2003) 655-663
54. Fadok V., Bratton D.L., Konowal A., et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J Clin Invest 101 (1998) 890-898
55. Paik Y.H., Schwabe R.F., Bataller R., et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37 (2003) 1043-1055
56. Wilson H.M., Chettibi S., Jobin C., Walbaum D., Rees A.J., and Kluth D.C. Inhibition of macrophage nuclear factor-kappaB leads to a dominant anti-inflammatory phenotype that attenuates glomerular inflammation in vivo. Am J Pathol 167 1 (2005) 27-37
57. Sakaida I., Terai S., Yamamoto N., Aoyama K., Ishikawa T., Nishina H., et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 40 6 (2004) 1304-1311
58. Yoshiji H., Kuriyama S., Miyamoto Y., Thorgeirsson U.P., Gomez D.E., Kawata M., et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 32 6 (2000) 1248-1254
59. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 36 4 Pt 1 (2002) 850-860
60. Iredale J.P. Hepatic stellate cell behaviour during resolution of liver fibrosis. Semin Liver Dis 21 (2001) 427-436
61. Issa R., Zhou X., Constandinou C., et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126 (2004) 1795-1808
62. Iredale J.P., Benyon R.C., Pickering J., et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 102 (1998) 538-549
63. Issa R., Williams E., Trim N., et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 48 (2001) 548-557
64. Oakley F., Trim N., Constandinou C.M., Ye W., Gray A.M., Frantz G., et al. Hepatocytes express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis. Am J Pathol 163 5 (2003) 1849-1858
65. Trim N., Morgan S., Evans M., Issa R., Fine D., Afford S., et al. Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. Am J Pathol 156 4 (2000) 1235-1243
66. Fischer R., Cariers A., Reinehr R., and Häussinger D. Caspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology 123 3 (2002) 845-861
67. Issa R., Zhou X., Trim N., Millward-Sadler H., Krane S., Benyon C., et al. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J 17 1 (2003) 47-49
68. Fallowfield J.A., Mizuno M., Kendall T.J., Constandinou C.M., Benyon R.C., Duffield J.S., et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol 178 8 (2007) 5288-5295
69. Rudolph K.L., Chang S., Millard M., Schreiber-Agus N., and DePinho R.A. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 287 5456 (2000) 1253-1258
70. Schnabl B., Purbeck C.A., Choi Y.H., Hagedorn C.H., and Brenner D. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology 37 3 (2003) 653-664
71. Williams E.J., Benyon R.C., Trim N., Hadwin R., Grove B.H., Arthur M.J., et al. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 49 4 (2001) 577-583
72. Elsharkawy A.M., Oakley F., and Mann D.A. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 10 5 (2005) 927-939 [Review]
73. Kallwitz E.R., McLachlan A., and Cotler S.J. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 14 1 (2008) 22-28 [Review]
74. Zhao C., Chen W., Yang L., Chen L., Stimpson S.A., and Diehl A.M. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 350 2 (2006) 385-391
75. Yavrom S., Chen L., Xiong S., Wang J., Rippe R.A., and Tsukamoto H. Peroxisome proliferator-activated receptor gamma suppresses proximal alpha1(I)collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells. J Biol Chem 280 49 (2005) 40650-40659
76. Marra F., Efsen E., Romanelli R.G., Caligiuri A., Pastacaldi S., Batignani G., et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119 2 (2000) 466-478
77. Warner F.J., Lubel J.S., McCaughan G.W., and Angus P.W. Liver fibrosis: a balance of ACEs?. Clin Sci (Lond) 113 3 (2007) 109-118 [Review]
78. Paizis G., Gilbert R.E., Cooper M.E., Murthi P., Schembri J.M., Wu L.L., et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 35 3 (2001) 376-385
79. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34 4 Pt 1 (2001) 745-750
80. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40 5 (2004) 1222-1225
81. Yang L., Jung Y., Omenetti A., Witek R.P., Choi S., Vandongen H.M., et al. Fate-mapping evidence that hepatic stellate cells are epithelial progenitors in adult mouse livers. Stem Cells (2008) [Epub ahead of print]
82. Iredale J.P. Science, medicine and the future: cirrhois: new research provides a basis for rational and targeted treatments. BMJ 327 (2003) 143-147